News Releases

August 16, 2021
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
Initiated Phase 2 open-label clinical study (APEX) for bezuclastinib (CGT9486) in patients with Advanced Systemic Mastocytosis (AdvSM) SUMMIT study for patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) on track to start 2H 2021 following recent positive interactions with FDA Formed Cogent
July 27, 2021
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , July 27, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will
June 29, 2021
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , June 29, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will
May 26, 2021
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , May 26, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present
May 12, 2021
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7
May 3, 2021
Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer
CAMBRIDGE , Mass. and BOULDER, Colo. , May 3, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role,
April 6, 2021
Cogent Biosciences Announces Creation of Cogent Research Team
Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million
March 16, 2021
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR,
February 22, 2021
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors
CAMBRIDGE, Mass. , Feb. 22, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Todd E. Shegog to its Board of Directors.
February 18, 2021
Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021
CAMBRIDGE, Mass. , Feb. 18, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present at the 10 th
Displaying 1 - 10 of 11
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.